PDL1expressing

PDL1expressing refers to cells or tissues that produce or display the protein programmed death‑ligand 1 (PD‑L1) on their cell surface. PD‑L1, also known as CD274, is a transmembrane protein that binds to the programmed death‑1 (PD‑1) receptor on T cells, delivering an inhibitory signal that dampens immune responses. This pathway is a key mechanism of peripheral tolerance, preventing autoimmunity, and is also exploited by tumors to evade immune surveillance.

PD‑L1 expression is induced by inflammatory stimuli, particularly interferon‑γ, and is regulated at transcriptional and post‑translational levels. In normal physiology, PD‑L1 is found on various cell types, including antigen‑presenting cells such as dendritic cells and macrophages, endothelial cells, and certain epithelial cells. Its expression patterns are dynamic and can change during development, infection, and inflammation.

In oncology, many cancer types—including lung, breast, melanoma, and renal cell carcinoma—display upregulated PD‑L1 on tumor cells or associated stromal cells. High PD‑L1 expression in tumor tissues is often correlated with poorer prognosis but also predicts responsiveness to immune checkpoint inhibitors that block the PD‑1/PD‑L1 interaction. Pathological assessment of PD‑L1 expression, typically by immunohistochemistry, informs therapeutic decisions for patients receiving drugs such as nivolumab, pembrolizumab, or atezolizumab.

Research continues to refine the understanding of PD‑L1 regulation, the significance of soluble versus membrane‑bound forms, and the development of more specific biomarkers. By modulating the PD‑L1 pathway, clinicians aim to enhance antitumor immunity while maintaining self‑tolerance.